当前位置: 首页 >> 检索结果
2382. Care of Patients With New, Continuing, or Recurring Symptoms After Acute SARS-CoV-2 Infection.
This article summarizes the ACP/Annals COVID-19 Forum IX held on 24 May 2022.
2387. Effectiveness and Harms of Contraceptive Counseling and Provision Interventions for Women : A Systematic Review and Meta-analysis.
作者: Heidi D Nelson.;Amy Cantor.;Rebecca M Jungbauer.;Karen B Eden.;Blair Darney.;Katherine Ahrens.;Amanda Burgess.;Chandler Atchison.;Rose Goueth.;Rongwei Fu.
来源: Ann Intern Med. 2022年175卷7期980-993页
The effectiveness and harms of contraceptive counseling and provision interventions are unclear.
2388. A Longitudinal Study of COVID-19 Sequelae and Immunity: Baseline Findings.
作者: Michael C Sneller.;C Jason Liang.;Adriana R Marques.;Joyce Y Chung.;Sujata M Shanbhag.;Joseph R Fontana.;Haniya Raza.;Onyi Okeke.;Robin L Dewar.;Bryan P Higgins.;Katie Tolstenko.;Richard W Kwan.;Kathleen R Gittens.;Catherine A Seamon.;Genevieve McCormack.;Jacob S Shaw.;Grace M Okpali.;Melissa Law.;Krittin Trihemasava.;Brooke D Kennedy.;Victoria Shi.;J Shawn Justement.;Clarisa M Buckner.;Jana Blazkova.;Susan Moir.;Tae-Wook Chun.;H Clifford Lane.
来源: Ann Intern Med. 2022年175卷7期969-979页
A substantial proportion of persons who develop COVID-19 report persistent symptoms after acute illness. Various pathophysiologic mechanisms have been implicated in the pathogenesis of postacute sequelae of SARS-CoV-2 infection (PASC).
2390. Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin : A Cohort Study.
作者: HoJin Shin.;Sebastian Schneeweiss.;Robert J Glynn.;Elisabetta Patorno.
来源: Ann Intern Med. 2022年175卷7期927-937页
Evidence on the risk for cardiovascular events associated with use of first-line sodium-glucose cotransporter-2 inhibitors (SGLT-2i) compared with metformin is limited.
2391. Medicare Spending on Drugs With Accelerated Approval.
作者: Jeromie Ballreich.;Mariana Socal.;Charles L Bennett.;Martin W Schoen.;Antonio Trujillo.;Andrew Xuan.;Gerard Anderson.
来源: Ann Intern Med. 2022年175卷7期938-944页
The U.S. Food and Drug Administration provides accelerated approval to drugs on the basis of surrogate end points deemed to be "reasonably likely" to predict clinical benefit. To receive full approval, drugs must complete a confirmatory trial. Although most accelerated approved drugs ultimately receive full approval, others remain on the market without full approval for many years, and some are withdrawn before full approval is granted. Until confirmatory trials are completed and full approval is granted, there is uncertainty surrounding each drug's clinical benefits.
|